
a
Study
Odds Ratio
OR
95%–CI
Unclear RoB
de Lange de Klerk (1994) 1.67 [0.96; 2.89]
Jacobs (1994) 2.22 [1.00; 4.94]
Kainz (1996) 1.41 [0.45; 4.45]
Chapman (1999) 1.98 [0.72; 5.49]
Straumsheim (2000) 0.80 [0.34; 1.90]
Jacobs (2001) 1.84 [0.63; 5.36]
Yakir (2001) 5.50 [0.96; 31.62]
Bonne (2003) 0.87 [0.28; 2.73]
Bell (2004) 1.77 [0.66; 4.72]
Frass (2005) 3.13 [1.10; 8.86]
Jacobs(a) (2005) 0.80 [0.25; 2.57]
Thompson (2005) 1.94 [0.66; 5.64]
RE Model 1.63 [1.24; 2.14]
High RoB
Whitmarsh (1997) 1.72 [0.69; 4.34]
Rastogi(a) (1999) 1.36 [0.45; 4.10]
Rastogi(b) (1999) 0.53 [0.17; 1.69]
Cavalcanti (2003) 3.50 [0.55; 22.30]
Weatherley–Jones (2004) 1.47 [0.62; 3.47]
Jacobs(b) (2005) 3.84 [1.06; 13.90]
Fisher (2006) 1.33 [0.34; 5.30]
Sajedi (2008) 0.55 [0.09; 3.34]
Siebenwirth (2009) 0.49 [0.07; 3.65]
Brien (2010) 0.86 [0.16; 4.47]
RE Model 1.33 [0.90; 1.98]
RE Model 1.53 [1.22; 1.91]
0.1 0.5 1 2 10
Favours placebo
Favours homeopathy


b
Study
Odds Ratio
OR
95%–CI
Non–reliable evidence
de Lange de Klerk (1994) 1.67 [0.96; 2.89]
Kainz (1996) 1.41 [0.45; 4.45]
Chapman (1999) 1.98 [0.72; 5.49]
Straumsheim (2000) 0.80 [0.34; 1.90]
Yakir (2001) 5.50 [0.96; 31.62]
Bonne (2003) 0.87 [0.28; 2.73]
Frass (2005) 3.13 [1.10; 8.86]
Jacobs(a) (2005) 0.80 [0.25; 2.57]
Thompson (2005) 1.94 [0.66; 5.64]
RE Model 1.53 [1.09; 2.14]
Reliable evidence
Jacobs (1994) 2.22 [1.00; 4.94]
Jacobs (2001) 1.84 [0.63; 5.36]
Bell (2004) 1.77 [0.66; 4.72]
RE Model 1.98 [1.16; 3.38]
RE Model 1.63 [1.24; 2.14]
0.1 0.5 1 2 10
Favours placebo
Favours homeopathy